Heiko Runz
@heikorunz.bsky.social
genetics, medicine, drug discovery, bioethics
Reposted by Heiko Runz
2/7 Reeve MP et al. @mpreeve.bluesky.social @heikorunz.bsky.social @fimm-uh.bsky.social
Loss of CFHR5 function reduces the risk for age-related macular degeneration.
Nature Communications @natcomms.nature.com
🔗 doi.org/10.1038/s414...
Loss of CFHR5 function reduces the risk for age-related macular degeneration.
Nature Communications @natcomms.nature.com
🔗 doi.org/10.1038/s414...
Loss of CFHR5 function reduces the risk for age-related macular degeneration - Nature Communications
This study in the Finnish population reveals genetic reduction of the complement factor CFHR5 as enhancing retinal health and reducing the risk for age-related macular degeneration (AMD), suggesting n...
doi.org
August 18, 2025 at 10:09 AM
2/7 Reeve MP et al. @mpreeve.bluesky.social @heikorunz.bsky.social @fimm-uh.bsky.social
Loss of CFHR5 function reduces the risk for age-related macular degeneration.
Nature Communications @natcomms.nature.com
🔗 doi.org/10.1038/s414...
Loss of CFHR5 function reduces the risk for age-related macular degeneration.
Nature Communications @natcomms.nature.com
🔗 doi.org/10.1038/s414...
Reposted by Heiko Runz
Most interesting to me is insitro's divergence from many AI biotech peers by focusing on novel biology.
That is the far harder road — taking more time and resources than going after well-trodden biology.
But Koller has some strong thoughts on why it's a worthwhile challenge:
That is the far harder road — taking more time and resources than going after well-trodden biology.
But Koller has some strong thoughts on why it's a worthwhile challenge:
December 18, 2024 at 1:14 PM
Most interesting to me is insitro's divergence from many AI biotech peers by focusing on novel biology.
That is the far harder road — taking more time and resources than going after well-trodden biology.
But Koller has some strong thoughts on why it's a worthwhile challenge:
That is the far harder road — taking more time and resources than going after well-trodden biology.
But Koller has some strong thoughts on why it's a worthwhile challenge: